Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PolyTRIGG

Financiado

Cerrado

Bioactive block copolymer vesicles as pH triggerable nano particulate carriers...

Bioactive block copolymer vesicles as pH triggerable nano particulate carriers for cancer vaccination "Advanced designed vaccines have to combine proper antigen with the effective immune-stimulating agents (adjuvants) and delivery strategies in order to attain successful treatment. Presently, most vaccines are given as liquid form... ver más

30/06/2014

UNIVERSITAT BASEL

193K€

Presupuesto del proyecto: 193K€

Líder del proyecto

UNIVERSITAT BASEL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2014-06-30 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UNIVERSITAT BASEL

0.00€ | Lider

Proyectos interesantes

POLYMMUNE

Medical Technol...

Nanotechnology

150K€ Cerrado

NANOIMMUNE

Nanotechnology

Medical Technol...

2M€ Cerrado

PCIN-2016-025

Medical Technol...

Nanotechnology

100K€ Cerrado

Meta-Targeting

Medical Technol...

Nanotechnology

2M€ Cerrado

THERMONANO

Medical Technol...

Nanotechnology

2M€ Cerrado

GLYCOTREAT

Medical Technol...

Nanotechnology

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

UNIVERSITAT BASEL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 193K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "Advanced designed vaccines have to combine proper antigen with the effective immune-stimulating agents (adjuvants) and delivery strategies in order to attain successful treatment. Presently, most vaccines are given as liquid formulations by intramuscular administration. However, nano-sized carriers of antigens hold great promise to be more effective delivery systems. To achieve the desired anti-cancer therapy; the ideal antigen nano-carrier has to fulfil a number of requirements. First of all carriers need to be (hollow) particles like with diameters in the range 50-500 nm in order to be taken up by dendritic cells (antigen-presenting cells capable to induce immune response). To facilitate the development of cellular immune responses, vaccine antigen must be presented on MHC (Major Histocompatibility Complex) class I. To win the goal, the nano-carrier should selectively bind to these cells, and be taken up into endosomes. To doing this carriers should be able to display certain adjuvants as targeting and stimulating ligands on their surface, and be capable to release its cargo upon response to pH changes in the endosome. Furthermore, vesicles have to carry and release antigen (i.e. proteins) to target destination with minor side-effects (biocompatibility and non-toxicity of carrier are essential). Hence, it is the goal of proposed project to develop nano-carriers on the basis of block copolymer vesicles (polymersomes) that have all those features. The aim is to developed polymersomes based on amphiphilic poly(2-methyloxazoline) PMOXA or (polydimethysiloxane) PDMS blocks in combination with stimulus-responsive copolymers blocks and a tunable polymersome surface chemistry. Therefore, the final goal is to provide ""smart"" drug delivery system with versatile surface chemistry, which will allow the attachment/incorporation of different adjuvants (e.g. saponins) and consequently enable target delivery."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores